A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- Sanction of new antiviral drug brings hope and confusionon May 11, 2020 at 10:31 am
Those potential therapies include anti-inflammatory drugs used for arthritis and other autoimmune diseases, which help tamp down the patient’s immune response. COVID-19 patients often end up on ...
- Autoimmune Disease Drugs To Receiving Government Approvals At Higher Rates As The Demand And R&D Activities For The Drugs Increase by 2028on May 11, 2020 at 5:12 am
Research Nester released a report titled "Autoimmune Disease Drugs Market: Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global autoimmune disease drugs ...
- Approval of new antiviral drug brings hope and confusionon May 10, 2020 at 1:10 pm
As Raymond Schinazi watched Dr. Anthony Fauci reveal data from a highly anticipated clinical trial late last month, he knew he was witnessing history.
- NIH clinical trial tests remdesivir plus anti-inflammatory drug baricitinib for COVID-19on May 8, 2020 at 1:35 pm
A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for ...
- Doctors to study anti-inflammatory drug as potential COVID-19 treatmenton May 8, 2020 at 12:51 pm
Keck Medicine of USC physicians are launching a clinical trial to evaluate the efficacy and safety of baricitinib, an anti-inflammatory drug approved by ...
- New drug trial looks at remdesivir combined with anti-inflammatoryon May 8, 2020 at 12:32 pm
Miller The National Institute of Allergy and Infectious Disease has begun a trial looking at the effects of remdesivir combined with a second drug, called baricitinib, on treating COVID-19.
- NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19on May 8, 2020 at 12:20 pm
The trial is currently enrolling adults hospitalized with COVID-19 in the United States and is expected to study the treatment combination in more than 1,000 participants. Interest in remdesivir has ...
- USC Testing Anti-Inflammatory Drug To Treat COVID-19on May 6, 2020 at 12:30 pm
USC researchers are studying whether the anti-inflammatory drug baricitinib could be used to treat coronavirus patients. USC’s Keck School of Medicine announced Wednesday that it is looking at whether ...
- Global Anti-Rheumatics Market (2019 to 2026) - by Drug Class, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids & Typeon May 6, 2020 at 2:37 am
Rheumatics Market by Drug Class, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Type: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.
via Bing News